13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics
Thomas Powles(Queen Mary University of London), Sophie Wildsmith(AstraZeneca (United Kingdom)), Peter H. O’Donnell(University of Chicago), Michiel S. van der Heijden(Zorginstituut Nederland), Natasha Angra(AstraZeneca (United States)), Jonathan Cairns(Babraham Institute), Jill Walker(AstraZeneca (United Kingdom)), Arjun Vasant Balar(NYU Langone Health), Amod Gupta(Post Graduate Institute of Medical Education and Research), Marlon C. Rebelatto(AstraZeneca (Japan)), Marietta Scott(AstraZeneca (United Kingdom)), Christophe Massard(Institut Gustave Roussy), B. Turriziani(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k